BioLingus (Cayman) Limited (SUBL)
BioLingus (Cayman) Limited will go public soon, but the exact IPO date is still unknown.
IPO Price
$20.00
Shares Offered
360,000
Deal Size
$7.20M
SUBL Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
222.25M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Apr 30, 2022 | - | - | - |
| Apr 30, 2021 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSUBL News
- 1 year ago - Biotech BioLingus files for IPO - Market Watch
- 1 year ago - BioLingus IPO Registration Document (F-1) - SEC